Multiple Myeloma

Daratumumab Leads to Deep Responses Among Newly Diagnosed Black Patients With Multiple Myeloma

September 10, 2020

Adding the anti-CD38 antibody, daratumumab, to the standard of care regimen of lenalidomide, bortezomib, and dexamethasone, improved depth of response, stringent complete response , and minimal residual disease negativity, in a subgroup of Black patients who had newly diagnosed multiple myeloma, according to findings presented at the eighth annual Society of Hematologic Oncology meeting.

FDA Grants Priority Review to Melflufen for Triple-Class Refractory Multiple Myeloma

August 31, 2020

The FDA granted Priority Review to Melphalan flufenamide in combination with dexamethasone for the treatment of adult patients with multiple myeloma that is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

New Analysis of Somatic Alterations Identifies Low-Risk Multiple Myeloma Subgroup

August 08, 2020

A new study has identified genomic factors that appear to correlate with a better risk profile and better progression-free survival among patients with multiple myeloma. The findings, though preliminary, could someday lead to better patient empowerment and stratification.